58 related articles for article (PubMed ID: 25219760)
1. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.
Devillier R; Gelsi-Boyer V; Murati A; Prebet T; Rey J; Etienne A; D'Incan E; Charbonnier A; Blaise D; Mozziconacci MJ; Vey N
Am J Hematol; 2015 Jan; 90(1):E22-4. PubMed ID: 25219760
[No Abstract] [Full Text] [Related]
2. Myelodysplasia in younger adults: outlier or unique molecular entity?
Sallman DA; Padron E
Haematologica; 2017 Jun; 102(6):967-968. PubMed ID: 28566339
[No Abstract] [Full Text] [Related]
3. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
4. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes, version 2.2015.
Greenberg PL; Stone RM; Bejar R; Bennett JM; Bloomfield CD; Borate U; De Castro CM; Deeg HJ; DeZern AE; Fathi AT; Frankfurt O; Gaensler K; Garcia-Manero G; Griffiths EA; Head D; Klimek V; Komrokji R; Kujawski LA; Maness LJ; O'Donnell MR; Pollyea DA; Scott B; Shami PJ; Stein BL; Westervelt P; Wheeler B; Shead DA; Smith C;
J Natl Compr Canc Netw; 2015 Mar; 13(3):261-72. PubMed ID: 25736003
[TBL] [Abstract][Full Text] [Related]
6. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
[TBL] [Abstract][Full Text] [Related]
7. Genes break barrier between MDS and AML.
Haferlach C
Blood; 2015 Jan; 125(1):9-10. PubMed ID: 25554745
[No Abstract] [Full Text] [Related]
8. Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.
Mahadevan D; Sutton GR
Expert Opin Investig Drugs; 2015 May; 24(5):725-33. PubMed ID: 25724698
[TBL] [Abstract][Full Text] [Related]
9. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Emadi A; Faramand R; Carter-Cooper B; Tolu S; Ford LA; Lapidus RG; Wetzler M; Wang ES; Etemadi A; Griffiths EA
Am J Hematol; 2015 May; 90(5):E77-9. PubMed ID: 25651001
[TBL] [Abstract][Full Text] [Related]
10. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
[TBL] [Abstract][Full Text] [Related]
11. Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology.
Cho YU; Jang S; Seo EJ; Park CJ; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park SH; Park YM; Lee JK
Leuk Lymphoma; 2015; 56(8):2301-8. PubMed ID: 25487075
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplasia is in the niche: novel concepts and emerging therapies.
Bulycheva E; Rauner M; Medyouf H; Theurl I; Bornhäuser M; Hofbauer LC; Platzbecker U
Leukemia; 2015 Feb; 29(2):259-68. PubMed ID: 25394715
[TBL] [Abstract][Full Text] [Related]
13. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
[TBL] [Abstract][Full Text] [Related]
14. Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.
Chen E; Jiao C; Yu J; Gong Y; Jin D; Ma X; Cui J; Wu Z; Zhou J; Wang H; Su B; Ge J
Cancer Med; 2023 Dec; 12(24):21615-21626. PubMed ID: 38098254
[TBL] [Abstract][Full Text] [Related]
15. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Chretien AS; Devillier R; Granjeaud S; Cordier C; Demerle C; Salem N; Wlosik J; Orlanducci F; Gorvel L; Fattori S; Hospital MA; Pakradouni J; Gregori E; Paul M; Rochigneux P; Pagliardini T; Morey M; Fauriat C; Dulphy N; Toubert A; Luche H; Malissen M; Blaise D; Nunès JA; Vey N; Olive D
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050021
[TBL] [Abstract][Full Text] [Related]
16. Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients.
Wang L; Chu X; Wang J; An L; Liu Y; Li L; Xu J
Turk J Haematol; 2021 Aug; 38(3):188-194. PubMed ID: 33938209
[TBL] [Abstract][Full Text] [Related]
17. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
18. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML.
Chretien AS; Devillier R; Fauriat C; Orlanducci F; Harbi S; Le Roy A; Rey J; Bouvier Borg G; Gautherot E; Hamel JF; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Blaise D; Olive D
Oncoimmunology; 2017; 6(12):e1307491. PubMed ID: 29209559
[TBL] [Abstract][Full Text] [Related]
19. NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.
Chretien AS; Fauriat C; Orlanducci F; Rey J; Borg GB; Gautherot E; Granjeaud S; Demerle C; Hamel JF; Cerwenka A; von Strandmann EP; Ifrah N; Lacombe C; Cornillet-Lefebvre P; Delaunay J; Toubert A; Arnoulet C; Vey N; Olive D
Oncotarget; 2017 Jul; 8(30):49548-49563. PubMed ID: 28548938
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]